6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

December 9, 2019

Commission File Number: 001 - 38178

Zealand Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

Sydmarken 11
2860 Søborg (Copenhagen)
Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x            Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release (“company announcement”) of Zealand Pharma A/S or the Company, dated December 5, 2019, announcing the granting of warrants to employees and the CFO under the Zealand Pharma employee warrant program. The warrants are granted under the warrant program covered by the authority pursuant to Section 8.4 of Zealand’s Articles of Association, adopted at Zealand’s General Meeting on April 21, 2015.

Furnished as Exhibit 99.2 is a second Company press release, also dated December 5, 2019, that discloses information on transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons. Exhibit 99.3 provides further detail of the transaction. This relates to the granting of warrants to the CFO referenced in Exhibit 99.1.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Zealand Pharma A/S
By:	/s/ Matthew Dallas
	Name: Matthew Dallas
	Title:   Chief Financial Officer

Date: December 9, 2019

2

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release dated December 5, 2019 announcing the grant of warrants
99.2	Press release dated December 5, 2019 disclosing information about manager transactions
99.3	MDL — warrants

3

EX-99.1

Exhibit 99.1

Company announcement — No. 42 / 2019

Zealand Pharma grants new warrants under the employee warrant program

Copenhagen, December 5, 2019 — Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78) announces the granting of warrants to employees and the CFO. The warrants are granted under the warrant program covered by the authority pursuant to Section 8.4 of Zealand’s Articles of Association, adopted at Zealand’s General Meeting on April 21, 2015.

Grant of warrants

The warrant program is an incentive scheme reflecting Zealand’s objective to attract and retain first-rate employees and to help ensure shared short- and long-term interests for the management, employees, and shareholders of Zealand.

A total of 48,915 warrants have been granted, giving the rights to subscribe for up to 48,915 new Zealand shares with a nominal value of DKK 1 each, corresponding to 0.14% of Zealand’s total outstanding share capital. The exercise price is DKK 220.00, calculated as the closing price of Zealand’s shares on Nasdaq Copenhagen on December 4, 2019.

The warrants will vest annually over a three year period, and the exercise of the warrants may take place, in whole or in part, in defined time windows from December 5, 2020 up to and including December 5, 2024.

The exercise time windows for all granted warrants are defined as four times a year during a four-week window starting from the time of publication of either the Zealand’s annual report or quarterly or semi-annual reports (three, six and nine months respectively).

The total new warrants granted have a combined market value of DKK 3,400,570.80 calculated on the basis of the Black—Scholes model, including a four-year historic volatility of 41.9%, a four-year risk-free interest rate of -0.63% and a share price of DKK 220.00.

For further information, please contact:

Zealand Pharma Investor Relations

+45 50 60 38 00 investors@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication

lpm@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company’s business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.

EX-99.2

Exhibit 99.2

Company announcement — No. 43 / 2019

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, December 5, 2019 — Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78) has received information on transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

Please see the attached file.

For further information, please contact:

Zealand Pharma Investor Relations

+45 50 60 38 00 investors@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication

lpm@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company’s business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.

EX-99.3

Exhibit 99.3

Template for notification and public disclosure of transactions by persons discharging manage-rial responsibilities and persons closely associated with them Updated 5 March 2018 1. Details of the person discharging managerial responsibilities/person closely associated a) Name 2. Reason for the notification a) Position/status b) Initial notifica-tion/Amendment 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auc-tion monitor a) Name b) LEI 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instru-ment Identification code b) Nature of the transaction c) Price(s) and volume(s) Price(s) Volume(s) d) Aggregated information -Aggregated volume -Price e) Date of the transaction f) Place of the transaction